Using multi-omics to develop the next generation of cancer therapeutics

Promatix is a data driven company that uses multi-omic information to develop a strong pipeline of novel therapeutics. We are particularly interested in the proteome, and using this in combination with other forms of omic information to gain insight into how these can vary in health and disease.

Our technology

Promatix's database, TxPro, has the largest known collection of proprietary proteomic data for oncology. Promatix mines TxPro to access novel drug targets that have the potential to transform the treatment of cancer.

Latest news

October 19, 2022

Promatix and Jasmin Fisher Lab at University College London Accelerate Hunt for Oncology Therapeutics with New Algorithms for CipherPro.

March 8, 2021

Promatix launches to develop next generation novel oncology therapeutics